1. [VNUT Is a Therapeutic Target for Type 2 Diabetes and NASH].
- Author
-
Hasuzawa N, Tatsushima K, Tokubuchi R, Kabashima M, and Nomura M
- Subjects
- Adenosine Triphosphate metabolism, Animals, Clodronic Acid pharmacology, Clodronic Acid therapeutic use, Drug Discovery, Humans, Insulin Resistance genetics, Insulin Secretion genetics, Mice, Knockout, Nucleotide Transport Proteins antagonists & inhibitors, Secretory Vesicles metabolism, Mice, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 genetics, Molecular Targeted Therapy, Non-alcoholic Fatty Liver Disease drug therapy, Non-alcoholic Fatty Liver Disease genetics, Nucleotide Transport Proteins physiology
- Abstract
ATP, used in cells as an energy currency, also acts as an extracellular signaling molecule. Studies of purinergic receptor subtypes have revealed that purinergic chemical transmission plays important roles in various cell types. The vesicular nucleotide transporter (VNUT), the ninth transporter in the SLC17 organic anion transporter family, is essential for vesicular ATP storage and its subsequent release. The VNUT is localized on the membrane of secretory vesicles and actively transports ATP into vesicles using an electrochemical gradient of protons supplied by vacuolar proton ATPase (V-ATPase) as a driving force. ATP acts as a damage-associated molecular pattern (DAMPs), contributing to the persistence of chronic inflammation. Chronic inflammation induces systemic insulin resistance, which is the underlying pathology of type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). We previously demonstrated that ATP transported in insulin granules via the VNUT negatively regulates insulin secretion. We also found that hepatocytes release ATP in a VNUT-dependent manner, which elicits hepatic insulin resistance and inflammation. VNUT-knockout mice exhibited improved glucose tolerance and were resistant to the development of high fat diet-induced NAFLD. In this article, we summarize recent advances in our understanding of the mechanism of the VNUT, the development of inhibitors, and its pathological involvement in type 2 diabetes and NAFLD. The pharmacological inhibition of the VNUT may represent a potential therapeutic approach for the treatment of metabolic diseases.
- Published
- 2021
- Full Text
- View/download PDF